Trastuzumab: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett mNo edit summary |
mNo edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]] and [[chemotherapy]], '''trastuzumab''' (pronounced tras too' zoo mab), '''Herceptin''' ®, is a [[monoclonal antibody]] against the [[ErbB-2 receptor]] (HER2) that lengthens remission time in metastatic [[breast cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 1 | pages= 39-51 | pmid=17611206 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17611206 | doi=10.1056/NEJMra043186 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17611206 | doi=10.1056/NEJMra043186 }} </ref> | ||
==External links== | |||
{{CZMed}} | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 11:00, 30 October 2024
In medicine and chemotherapy, trastuzumab (pronounced tras too' zoo mab), Herceptin ®, is a monoclonal antibody against the ErbB-2 receptor (HER2) that lengthens remission time in metastatic breast cancer.[1]
External links
The most up-to-date information about Trastuzumab and other drugs can be found at the following sites.
- Trastuzumab - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Trastuzumab - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Trastuzumab - Detailed information from DrugBank.
References
- ↑ Hudis CA (2007). "Trastuzumab--mechanism of action and use in clinical practice.". N Engl J Med 357 (1): 39-51. DOI:10.1056/NEJMra043186. PMID 17611206. Research Blogging.